Inapsine

"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.

What should I discuss with my health care provider before receiving droperidol (Inapsine)?

You should not be given this medication if you are allergic to droperidol, or have a personal or family history of "Long QT syndrome."

Before you receive droperidol, tell your doctor if you are allergic to any drugs, or if you have:

heart disease;

heart rhythm disorder;

congestive heart failure;

high blood pressure;

an electrolyte imbalance (such as low potassium);

liver or kidney disease;

adrenal gland cancer (pheochromocytoma); or

a history of alcohol abuse.

If you have any of these conditions, you may not be able to receive droperidol, or you may need a dose adjustment.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Before you receive droperidol, tell your doctor if you are pregnant.

It is not known whether droperidol passes into breast milk or if it could harm a nursing baby. Before you receive this medication, tell your doctor if you are breast-feeding a baby.

How is droperidol given (Inapsine)?

Droperidol is given as an injection through a needle placed into a muscle or a vein. You will receive this injection in a clinic or hospital setting prior to and/or during your surgery or medical procedure.